139 related articles for article (PubMed ID: 9148412)
41. [Protective effect of coli-proteus vaccine in an experimental animal model].
Bĕlohlávek S; Konícková L
Cesk Farm; 1980 May; 29(3-4):95-9. PubMed ID: 6996844
[No Abstract] [Full Text] [Related]
42. [The role of E. coli adhesiveness in the pathogenesis and clinical course of urinary tract infections].
Krzeska I; Ostojska J; Dzierzanowska D
Pol Tyg Lek; 1992 Aug 7-17; 47(31-33):706-9. PubMed ID: 1362812
[TBL] [Abstract][Full Text] [Related]
43. [Candidate vaccine against urinary tract infections].
Hoepelman IM; Meiland R; Langermann S
Ned Tijdschr Geneeskd; 2001 Sep; 145(38):1860-2. PubMed ID: 11593791
[TBL] [Abstract][Full Text] [Related]
44. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
Billips BK; Yaggie RE; Cashy JP; Schaeffer AJ; Klumpp DJ
J Infect Dis; 2009 Jul; 200(2):263-72. PubMed ID: 19522648
[TBL] [Abstract][Full Text] [Related]
45. Antibody response of children with enteropathogenic Escherichia coli infection to the bundle-forming pilus and locus of enterocyte effacement-encoded virulence determinants.
Martinez MB; Taddei CR; Ruiz-Tagle A; Trabulsi LR; Girón JA
J Infect Dis; 1999 Jan; 179(1):269-74. PubMed ID: 9841853
[TBL] [Abstract][Full Text] [Related]
46. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
[TBL] [Abstract][Full Text] [Related]
47. Immune responses to new vaccine candidates constructed by a live attenuated Salmonella Typhimurium delivery system expressing Escherichia coli F4, F5, F6, F41 and intimin adhesin antigens in a murine model.
Hur J; Lee JH
J Vet Med Sci; 2011 Oct; 73(10):1265-73. PubMed ID: 21628866
[TBL] [Abstract][Full Text] [Related]
48. Recombinant DNA technology and enterotoxigenic Escherichia coli vaccines.
Gyles CL; Maas WK
Prog Vet Microbiol Immunol; 1987; 3():139-58. PubMed ID: 3078832
[No Abstract] [Full Text] [Related]
49. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
[TBL] [Abstract][Full Text] [Related]
50. Systemic and mucosal antibody responses to selected cell surface antigens of avian pathogenic Escherichia coli in experimentally infected chickens.
Kariyawasam S; Wilkie BN; Hunter DB; Gyles CL
Avian Dis; 2002; 46(3):668-78. PubMed ID: 12243531
[TBL] [Abstract][Full Text] [Related]
51. [Urinary tract infections and their prevention].
González-Chamorro F; Palacios R; Alcover J; Campos J; Borrego F; Dámaso D
Actas Urol Esp; 2012 Jan; 36(1):48-53. PubMed ID: 21757260
[TBL] [Abstract][Full Text] [Related]
52. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.
Russo TA; McFadden CD; Carlino-MacDonald UB; Beanan JM; Olson R; Wilding GE
Infect Immun; 2003 Dec; 71(12):7164-9. PubMed ID: 14638809
[TBL] [Abstract][Full Text] [Related]
53. [Prospects for the production of an anti-adhesive vaccine against strains of Escherichia coli causing diarrhea in humans (1)].
Cravioto A
Bol Med Hosp Infant Mex; 1984 Mar; 41(3):122-8. PubMed ID: 6144315
[No Abstract] [Full Text] [Related]
54. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli.
Evans DG; Graham DY; Evans DJ
Gastroenterology; 1984 Oct; 87(4):934-40. PubMed ID: 6381216
[TBL] [Abstract][Full Text] [Related]
55. Effect of immunization with Escherichia coli K1 antigen on the course of experimental infection of the urinary tract of the rat.
Straube E; Nimmich W; Broschewitz U; Naumann G; Hacker K
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jul; 265(3-4):408-19. PubMed ID: 3314264
[TBL] [Abstract][Full Text] [Related]
56. Synthetic peptides protect against infection in a model of experimental pyelonephritis in mice.
Schmidt MA; O'Hanley P; Schoolnik GK
Ann Sclavo Collana Monogr; 1986; 3(1-2):389-98. PubMed ID: 3322342
[No Abstract] [Full Text] [Related]
57. Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice.
Gao X; Cai K; Li T; Wang Q; Hou X; Tian R; Liu H; Tu W; Xiao L; Fang L; Luo S; Liu Y; Wang H
Vaccine; 2011 Sep; 29(38):6656-63. PubMed ID: 21742003
[TBL] [Abstract][Full Text] [Related]
58. Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed enterotoxigenic Escherichia coli fimbrial antigens.
Tobias J; Lebens M; Wai SN; Holmgren J; Svennerholm AM
Microb Pathog; 2017 Apr; 105():177-184. PubMed ID: 28215587
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of a recombinant Intimin, EspB and Shiga toxin 2B vaccine in calves experimentally challenged with Escherichia coli O157:H7.
Martorelli L; Garimano N; Fiorentino GA; Vilte DA; Garbaccio SG; Barth SA; Menge C; Ibarra C; Palermo MS; Cataldi A
Vaccine; 2018 Jun; 36(27):3949-3959. PubMed ID: 29807709
[TBL] [Abstract][Full Text] [Related]
60. First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS).
Wieser A; Magistro G; Nörenberg D; Hoffmann C; Schubert S
Int J Med Microbiol; 2012 Jan; 302(1):10-8. PubMed ID: 22000741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
